2016
TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer
Elbaz M, Ahirwar D, Xiaoli Z, Zhou X, Lustberg M, Nasser M, Shilo K, Ganju R. TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. Oncotarget 2016, 9: 33459-33470. PMID: 30323891, PMCID: PMC6173360, DOI: 10.18632/oncotarget.9663.Peer-Reviewed Original ResearchTriple-negative breast cancerTransient receptor potential vanilloid type-2Negative breast cancerTNBC patientsTRPV2 expressionBreast cancerHigher recurrence-free survivalRecurrence-free survivalLimited therapeutic optionsGood prognostic markerEfficacy of chemotherapyNovel therapeutic strategiesNormal breast tissueMouse model studiesFree survivalNegative patientsAggressive diseaseTherapeutic optionsCancer patientsTNBC tumorsPrognostic markerTNBC tissuesTRPV2 activationNovel biomarkersTherapeutic strategies
2012
Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy
Garcia-Villa A, Balasubramanian P, Miller B, Lustberg M, Ramaswamy B, Chalmers J. Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy. Frontiers In Oncology 2012, 2: 128. PMID: 23112954, PMCID: PMC3480704, DOI: 10.3389/fonc.2012.00128.Peer-Reviewed Original ResearchStage IV breast cancerTumor cellsBreast cancer patientsPlatinum-based therapySolid tumor malignanciesPotential of CTCsSurface markers CD45Γ-H2AXDNA-damaging therapiesΓ-H2AX levelsPlatinum therapyPeripheral bloodCancer patientsPredictive markerPatient outcomesPrognostic markerBreast cancerΓ-H2AX stainingPatient's conditionTumor malignancyTherapyNegative depletionLiquid biopsyStaining patternCell apoptosis